Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULYSSE: Fruquintinib vs Bevacizumab in 2nd-line mCRC
NCT07150403Phase 2Not yet recruiting
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Dec 2025
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fruquintinib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Disease Control Rate at 4 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07150403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150403.